MedCity News November 26, 2024
Pricy GLP-1 medications are here to stay — let’s focus on turning their potential into lasting, meaningful impact.
For the nearly 42% of U.S. adults grappling with obesity, scientific advances in treatment have opened a new chapter in care. Among these breakthroughs, GLP-1 medications have emerged as transformative tools, enabling significant weight loss and notable cardiometabolic improvements. However, this progress comes with a steep cost — an average annual cost of $9,000 per patient.
Despite the high price tag, long-term outcomes remain uncertain. Data shows that patients regain, on average, two-thirds of their lost weight within a year of discontinuing GLP-1 therapy. This reversal often comes with a return of obesity-related health risks, diminishing the clinical and financial gains that...
Today's Sponsors
Today's Sponsor